News and press releases from HAPILA
Anti Tuberculosis Agent BTZ-043 commences Clinical Phase II
Since mid-November TB patients have been treated for the first time with the new substance BTZ-043 in Cape Town, South Africa. The study is being conducted in the PanACEA consortium in collaboration with the TASK Applied Science...[more]
HAPILA showcases advanced API synthesis expertise at CPhI Worldwide Frankfurt
HAPILA GmbH will again be an innovative presence at the huge CPhI Worldwide pharmaceutical fair, showcasing its abilities to develop drug substances at every step of the value chain. We will be an exhibitor in the API zone of the...[more]
HAPILA gains DIN ISO certification
HAPILA GmbH has passed a further significant milestone to ensure a high quality level for their offered services and products. The TÜV Thüringen e.V. (Technical Supervision Association Thuringia) has granted a DIN ISO...[more]
FDA Inspection Successfully Passed
In 2019 HAPILA GmbH had the first in-house GMP inspection by the American Health Authority FDA lasting several days. During this inspection our company was checked for compliance with the USFDA requirements ("facility for...[more]
IQ Innovation Award of Central Germany for Novel Pharmaceutical Ingredient against Tuberculosis
The innovation of the year 2019 in central Germany is a novel active pharmaceutical ingredient against tuberculosis pathogens. It is being developed as a drug by a team of researchers of the Leibniz Institute for Natural Product...[more]
HAPILA at Chemspec Europe 2019, Basel
HAPILA is returning to the Chemspec Europe trade fair for fine and specialty chemicals in Basel to showcase its GMP drug development and manufacturing services. We will exhibit from Booth C36 in Hall 1.0 at Messe Basel as part of...[more]
Thuringian Pharma Community: complete value creation chains in Thuringia
The potential of the Thuringian pharmaceutical industry shall become more visible At their spring meeting this year the Thuringian Pharma Community submitted a concrete plan to strengthen the pharmaceutical industry within the...[more]